lung
transplant
becom
import
therapeut
option
patient
endstag
organ
dysfunct
howev
clinic
use
limit
rel
earli
onset
chronic
allograft
dysfunct
progress
clinic
declin
oblit
bronchiol
character
histolog
lumin
fibrosi
respiratori
bronchiol
clinic
bronchiol
obliteran
syndrom
bo
defin
measur
declin
lung
function
base
forc
expiratori
volum
fev
sinc
earliest
descript
number
risk
factor
associ
develop
bo
includ
acut
reject
lymphocyt
bronchiol
primari
graft
dysfunct
infect
donor
specif
antibodi
gastroesophag
reflux
diseas
howev
despit
broaden
understand
pathogenesi
underli
bo
remain
poorli
understood
begun
rel
treatment
option
battl
progress
deterior
lung
function
lung
transplant
becom
import
therapeut
option
patient
endstag
organ
dysfunct
oneyear
adjust
graft
surviv
rate
steadili
increas
within
last
ten
year
greater
despit
shortterm
success
longterm
outcom
fail
attain
longev
similar
solid
organ
transplant
recipi
pulmonari
allograft
fare
far
wors
solid
organ
per
current
intern
societi
heart
lung
transplant
ishlt
registri
data
approxim
patient
develop
evid
chronic
dysfunct
within
five
year
transplant
notabl
declin
surviv
time
fact
chronic
reject
account
greater
late
death
occur
first
year
transplant
first
elucid
chronic
lung
allograft
dysfunct
clad
domin
physiolog
descript
obstruct
lung
diseas
histopatholog
oblit
bronchiol
ob
fact
clad
consid
synonym
bronchiol
obliteran
syndrom
bo
howev
increasingli
recogn
clad
actual
univers
label
appli
patient
whose
forc
expiratori
volum
fev
andor
forc
vital
capac
fvc
less
equal
baselin
greater
equal
three
week
clarif
patient
subdivid
base
physiolog
fig
specif
patient
fall
within
restrict
clad
phenotyp
restrict
allograft
syndrom
obstruct
clad
phenotyp
bo
acknowledg
may
overlap
two
form
review
focu
obstruct
clad
bo
discuss
diagnosi
risk
factor
pathogenesi
treatment
earli
cohort
lung
heartlung
transplant
patient
diagnosi
chronic
reject
oblit
bronchiol
made
via
tissu
specimen
histopatholog
standpoint
ob
character
presenc
lumin
fibrosi
respiratori
bronchiol
suspect
fibrot
process
first
initi
lymphocyt
infiltr
submucosa
airway
due
inflammatori
insult
lead
local
necrosi
denud
respiratori
epithelium
subsequ
increas
nonspecif
inflammatori
mediat
lead
chemotaxi
cell
includ
neutrophil
stimul
migrat
fibroblast
myofibroblast
airway
lumen
eventu
format
intralumin
granul
tissu
fibrou
plaqu
result
lead
obliter
airway
due
vascular
scar
tissu
format
note
process
often
tempor
region
heterogen
within
allograft
histor
due
requir
histopatholog
diagnosi
chronic
reject
often
difficult
make
due
fact
histolog
confirm
challeng
obtain
transbronchi
biopsi
specimen
lack
sensit
requir
diagnosi
surgic
lung
biopsi
often
carri
high
morbid
mortal
therefor
committe
sponsor
ishlt
propos
clinic
descript
ob
term
bronchiol
obliteran
syndrom
bo
base
patient
posttranspl
fev
updat
clinic
diagnost
criteria
bo
revis
potenti
stage
bo
ad
defin
decreas
fev
andor
decreas
forc
expiratori
flow
fef
baselin
potenti
bo
stage
design
alert
physician
need
closer
function
monitor
patient
would
higher
risk
clinic
declin
bo
abl
defin
standard
easili
obtain
reproduc
spirometr
method
numer
studi
look
surrog
marker
bo
includ
bronchoalveolar
lavag
bal
neutrophilia
bal
biomark
level
mmp
exhal
nitric
oxid
radiolog
find
airtrap
highresolut
ct
chest
bronchial
hyperrespons
via
methacholin
challeng
circul
fibrocyt
level
none
routin
use
clinic
practic
diagnosi
acut
reject
ar
repeatedli
shown
lead
risk
factor
bo
multipl
studi
arguabl
promin
risk
factor
identifi
literatur
ar
vari
clinic
present
howev
also
associ
spirometr
fig
evalu
lung
transplant
recipi
declin
may
secondari
identifi
caus
eg
acut
reject
infect
anastomot
strictur
lung
function
may
complet
normal
treatment
underli
patholog
howev
patient
lung
function
declin
remain
least
three
week
suggest
chronic
lung
allograft
dysfunct
clad
declin
recipi
best
posttransplant
valu
despit
treatment
without
identifi
clear
caus
specif
clad
phenotyp
restrict
obstruct
delin
base
recipi
pulmonari
function
test
form
lung
dysfunct
howev
mutual
exclus
patient
may
featur
phenotyp
abbrevi
forc
expiratori
volum
one
second
fvcforc
vital
capac
tlctotal
lung
capac
signific
acut
decreas
baselin
function
patient
even
greater
risk
bo
death
sever
studi
shown
larg
airway
inflamm
lymphocyt
bronchiol
also
significantli
associ
bo
shown
risk
factor
independ
acut
reject
due
associ
also
suggest
presenc
lymphocyt
bronchiol
endobronchi
biopsi
even
obtain
clinic
asymptomat
patient
may
indic
increas
risk
bo
popul
target
aggress
manag
prevent
allograft
declin
solid
organ
undergo
period
ischemia
prior
transplant
data
small
studi
gener
shown
neither
warm
cold
ischemia
time
significantli
correl
bo
howev
vascularmedi
injuri
newli
transplant
allograft
also
occur
form
primari
graft
dysfunct
pgd
ischemia
reperfus
injuri
form
acut
lung
injuri
occur
patient
transplant
grade
clinic
base
pao
fio
ratio
appear
radiograph
infiltr
chest
imag
earli
studi
regard
associ
pgd
bo
conflict
recent
work
conclud
direct
relationship
sever
pgd
risk
bo
independ
recogn
risk
factor
includ
acut
reject
lastli
ischemia
airway
also
take
chronic
form
due
natur
surgic
oper
normal
lung
dual
blood
suppli
compos
pulmonari
bronchial
arteri
circul
routin
pulmonari
circul
undergo
reanastomosi
landmark
european
studi
coupl
data
one
north
american
center
pettersson
et
al
describ
superior
surviv
patient
underw
bronchial
arteri
revascular
bar
time
transplant
group
success
improv
airway
heal
compar
control
bo
delay
two
year
greater
led
suggest
wide
adopt
practic
perform
bar
time
transplant
reduc
incid
airway
ischem
complic
futur
multitud
pulmonari
infect
affect
lung
transplant
patient
cytomegaloviru
cmv
wide
studi
howev
despit
suspect
contributor
chronic
reject
earli
studi
assess
impact
cmv
infect
bo
inconclus
due
wide
rang
clinic
definit
util
sinc
time
howev
multipl
studi
shown
cmv
significantli
associ
bo
develop
cmv
prophylaxi
clearli
associ
decreas
rate
bo
may
secondari
lower
incid
clinic
appar
diseas
cmv
pneumon
howev
advent
molecular
diagnost
tool
polymeras
chain
reaction
pcr
detect
subclin
cmv
replic
even
asymptomat
viral
activ
significantli
associ
develop
bo
subsequ
rais
question
exact
time
length
prophylaxi
especi
highrisk
individu
interestingli
rel
studi
look
associ
pulmonari
infect
bo
time
infect
import
pneumonia
caus
gramposit
gramneg
fungal
pathogen
independ
determin
bo
especi
occur
within
first
day
transplant
one
studi
also
report
associ
worsen
bo
stage
infect
occur
start
allograft
declin
even
though
lung
transplant
patient
particularli
suscept
complic
respiratori
viral
infect
analysi
preexist
studi
fail
confirm
true
associ
respiratori
viral
infect
influenza
respiratori
syncyti
viru
parainfluenza
human
metapneumoviru
rhinoviru
coronaviru
adenoviru
either
acut
reject
develop
bo
airway
colon
necessarili
infect
pathogen
organ
also
close
link
bo
develop
vo
et
al
show
retrospect
studi
postop
colon
airway
pseudomona
aeruginosa
independ
risk
factor
bo
stage
associ
wors
bosfre
surviv
especi
patient
cystic
fibrosi
underli
caus
endstag
lung
diseas
de
novo
colon
pseudomona
aeruginosa
also
strongli
associ
subsequ
develop
bo
fungal
infect
colon
aspergillu
speci
shown
risk
factor
bo
independ
acut
reject
find
later
verifi
twocent
studi
specifi
small
conidia
speci
aspergillu
fumigatu
nidulan
terreu
flavip
significantli
associ
bo
colon
small
conidia
speci
also
associ
increas
risk
death
hsu
et
al
hypothes
aspergillu
capac
grow
hypox
environ
could
modul
host
immun
repair
respons
allograft
demonstr
murin
tracheal
transplant
model
fumigatu
invas
increas
progress
airway
ischemia
turn
worsen
region
perfus
infect
area
howev
investig
lung
microbiom
molecular
sequenc
standpoint
argu
develop
bo
necessarili
link
specif
organ
rather
acquisit
novel
atyp
microbi
popul
alter
host
nativ
pretranspl
microbiota
within
recent
year
clinic
signific
donorspecif
antibodi
dsa
pathogenesi
chronic
allograft
dysfunct
receiv
increas
attent
earli
associ
bo
human
leukocyt
antigen
hla
mismatch
b
dr
loci
clear
major
evid
conflict
natur
limit
singlecent
studi
inadequ
power
hla
class
ii
mismatch
donor
recipi
develop
antihla
class
antibodi
lung
transplant
increas
frequenc
alloreact
cell
identifi
signific
risk
factor
develop
bo
studi
howev
larg
retrospect
analysi
lung
registri
data
fail
show
consist
associ
thu
presenc
dsa
hla
antigen
defin
posit
panel
reactiv
antibodi
pra
screen
felt
potenti
risk
factor
bo
nonetheless
sinc
time
chalermskulrat
et
al
show
number
combin
hlaa
hlab
mismatch
strongli
associ
bo
stage
trend
toward
signific
seen
hladr
mismatch
numer
clinic
studi
also
shown
dsa
undoubtedli
associ
acut
antibodi
mediat
reject
amr
bo
antibodi
nonhla
antigen
implic
pathogenesi
bo
well
hagedorn
et
al
show
profil
autoantibodi
abl
distinguish
patient
bo
stage
bo
stage
fact
autoallo
immun
cryptic
selfantigen
type
v
collagen
tublin
present
signific
number
patient
bo
although
unclear
antibodi
act
directli
injuri
epithelium
mere
serv
marker
ongo
immunolog
damag
gastroesophag
reflux
diseas
gerd
first
identifi
hypothet
risk
factor
due
postul
aspir
acid
could
caus
direct
injuri
respiratori
epithelium
earli
case
report
suggest
aggress
treatment
reflux
could
lead
revers
patient
clinic
declin
key
studi
davi
et
al
show
perform
nissen
fundopl
patient
document
gerd
lung
transplant
improv
surviv
allograft
function
decreas
bo
stage
howev
blondeau
et
al
show
patient
gerd
necessarili
increas
risk
bo
elev
level
bile
acid
bal
fluid
suggest
necessarili
presenc
gerd
would
predispos
patient
bo
rather
concurr
act
aspir
would
lead
increas
risk
diseas
sinc
studi
gerd
assess
via
ph
monitor
imped
manometri
esophagogastroduodenoscopi
egd
shown
associ
develop
bo
bosfre
surviv
group
also
show
patient
signific
reflux
also
increas
delayedtyp
hypersensit
reaction
type
v
collagen
suggest
acid
caus
direct
injuri
respiratori
epithelium
also
unmask
cryptic
antigen
drive
damag
immunolog
respons
howev
although
wide
employ
use
protonpump
inhibitor
ppi
shown
prevent
nonacid
reflux
gastric
aspir
numer
retrospect
studi
look
donorrel
factor
whether
associ
develop
bo
one
largest
retrospect
review
uno
databas
patient
author
show
donorrel
factor
significantli
associ
bo
fiveyear
posttransplant
includ
receiv
organ
older
donor
year
recent
smoker
smokedquit
within
six
month
donat
individu
histori
myocardi
infarct
interestingli
high
donor
also
associ
higher
rate
develop
bo
donor
gender
also
studi
trend
increas
surviv
demonstr
gender
mismatch
recipi
maletomal
transplant
recipi
worst
overal
surviv
femaletofemal
recipi
donor
combin
independ
associ
increas
freedom
bo
longer
durat
bosfre
surviv
rel
maletomal
recipi
donor
combin
adjust
cumul
incid
bo
similar
nonetheless
find
specif
chang
organ
alloc
particular
recipi
lastli
contrast
major
solid
organ
transplant
lung
direct
contact
environ
nawrot
et
al
describ
patient
live
within
meter
lowest
tertil
major
road
defin
highway
nation
road
larg
local
road
approxim
twice
like
develop
bo
twice
like
die
patient
live
away
point
associ
environment
exposur
direct
injuri
declin
allograft
dysfunct
despit
elucid
numer
risk
factor
outlin
exact
pathogenesi
bo
elucid
like
howev
injuri
remodel
repair
occur
stepwis
fashion
rather
complex
milieu
disord
interact
instanc
patient
pgd
higher
level
inflammatori
marker
earli
posttranspl
period
comparison
patient
without
pgd
interestingli
patient
also
develop
antihla
antibodi
higher
rate
would
put
higher
risk
acut
cellular
reject
antibodymedi
reject
lymphocyt
bronchiol
thu
bottom
line
pathophysiolog
associ
factor
link
common
pathway
upregul
inflammatori
cytokin
cellular
traffick
lead
epitheli
vascular
damag
notabl
bo
close
link
dysfunct
clara
cell
secretori
cell
present
bronchial
epithelium
contribut
host
defens
serv
progenitor
cell
repair
respiratori
epithelium
injuri
repeat
injuri
mechan
contribut
continu
inflamm
chang
cell
phenotyp
unmask
selfantigen
neoangiogenei
like
culmin
robust
derang
repair
process
chronic
remodel
airway
describ
develop
bo
influenc
multitud
factor
result
direct
indirect
injuri
respiratori
epithelium
vasculatur
therefor
surpris
rel
treatment
modal
shown
effect
slow
revers
process
modul
immun
respons
time
transplant
investig
studi
induct
therapi
lung
transplant
fail
show
consist
benefit
term
reduc
longterm
complic
incid
bo
posttranspl
period
bo
treat
varieti
medic
regimen
includ
limit
augment
immunosuppress
corticosteroid
methotrex
cyclophosphamid
sirolimu
antilymphocyt
antibodi
prepar
specif
mainten
immunosuppress
regimen
protocol
shown
superior
reduc
incid
bo
howev
metaanalys
suggest
trend
toward
lower
risk
patient
receiv
tacrolimu
versu
cyclosporin
calcineurininhibitor
base
regimen
result
demonstr
multicent
intern
prospect
trial
report
use
de
novo
tacrolimusbas
regimen
significantli
reduc
risk
bo
stage
nonetheless
result
limit
small
sampl
size
rel
lack
random
control
thu
current
formal
recommend
regard
use
one
calcineurin
inhibitor
anoth
gener
airway
chang
bo
consid
irrevers
occur
howev
case
may
respond
specif
treatment
instanc
larg
part
patient
declin
due
specif
etiolog
eg
gerd
specif
measur
aim
treat
underli
caus
may
amelior
revers
declin
lung
function
howev
gener
cohort
patient
sever
singlecent
studi
shown
signific
proport
patient
bo
respond
azithromycin
increas
least
patient
even
show
complet
revers
prior
physiolog
declin
return
bo
stage
role
macrolid
prevent
bo
also
examin
vo
et
al
studi
cohort
patient
therapi
azithromycin
versu
placebo
initi
time
discharg
initi
hospit
transplant
patient
maintain
medic
two
year
studi
develop
bo
occur
significantli
less
patient
receiv
chronic
azithromycin
therapi
versu
contrast
howev
dhillon
et
al
show
routin
use
clarithromycin
actual
associ
increas
risk
develop
bo
signific
chang
surviv
rescu
therapi
also
employ
includ
extracorpor
photopheresi
ecp
treatment
white
blood
cell
isol
recipi
expos
photoactivat
ultraviolet
radiat
cell
subsequ
return
patient
appear
induc
cytotox
effect
tcell
format
first
report
letter
editor
describ
use
three
patient
good
clinic
respons
sinc
time
sever
singlecent
studi
consist
demonstr
ecp
therapi
rel
welltoler
slow
rate
declin
howev
therapi
yet
util
widespread
clinic
practic
retransplant
remain
definit
treatment
advanc
bo
even
acknowledg
outcom
tend
poor
year
sinc
first
human
lung
transplant
perform
yet
chronic
lung
allograft
dysfunct
due
bronchiol
obliteran
syndrom
still
repres
major
hurdl
longterm
allograft
patient
surviv
outlin
numer
risk
factor
predispos
patient
develop
process
howev
pathogenesi
remain
poorli
understood
reflect
heterogen
present
patient
may
experi
rapid
declin
other
experi
slow
progress
deterior
lung
function
suspect
inflammatori
condit
whether
aris
infect
ischem
injuri
exposur
caus
direct
indirect
injuri
lead
disord
repair
airway
epithelium
treatment
option
exist
bo
becom
clinic
evid
specif
induct
mainten
immunosuppress
regimen
proven
superior
prevent
onset
retransplant
remain
definit
treatment
diseas
therefor
hope
understand
mechan
underli
process
allow
lung
transplant
viabl
longterm
therapeut
option
patient
endstag
lung
diseas
conflict
interest
christin
lin
martin
r
zamora
declar
conflict
interest
human
anim
right
inform
consent
studi
author
involv
anim
andor
human
subject
perform
approv
appropri
institut
review
board
requir
written
inform
consent
obtain
particip
